A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination.
Adjuvants, Immunologic
/ adverse effects
Autoantibodies
/ blood
BNT162 Vaccine
/ adverse effects
C-Peptide
/ blood
COVID-19
/ prevention & control
Diabetes Mellitus, Type 1
/ drug therapy
Diabetes Mellitus, Type 2
/ drug therapy
Glycated Hemoglobin
/ analysis
Glycemic Control
Graves Disease
/ etiology
Humans
Male
Middle Aged
Molecular Mimicry
/ immunology
SARS-CoV-2
/ immunology
Thyrotoxicosis
/ pathology
Vitiligo
/ pathology
Graves' disease
SARS-CoV-2
Type 1 diabetes mellitus
Vaccine
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
15
09
2021
revised:
06
10
2021
accepted:
06
10
2021
pubmed:
16
10
2021
medline:
29
12
2021
entrez:
15
10
2021
Statut:
ppublish
Résumé
Autoimmune diseases, including autoimmune endocrine diseases (AIED), are thought to develop following environmental exposure in patients with genetic predisposition. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccines against it could represent new environmental triggers for AIED. We report a patient, with history of vitiligo vulgaris and 8 years of type 2 diabetes, who came to our institution because of fever, weight loss, asthenia and thyrotoxicosis occurred 4 weeks later the administration of BNT162B2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Clinical, biochemical and instrumental work-up demonstrated Graves' disease and autoimmune diabetes mellitus. The occurrence of these disorders could be explained through different mechanism such as autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome), mRNA "self-adjuvant" effect, molecular mimicry between human and viral proteins and immune disruption from external stimuli. However further studies are needed to better understand the underlying pathogenesis of AIED following SARS-CoV-2 vaccine.
Identifiants
pubmed: 34653776
pii: S0896-8411(21)00146-3
doi: 10.1016/j.jaut.2021.102738
pmc: PMC8506108
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Autoantibodies
0
C-Peptide
0
Glycated Hemoglobin A
0
anti-GAD65 autoantibody
0
hemoglobin A1c protein, human
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102738Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
J Endocrinol Invest. 2022 Jan;45(1):227-228
pubmed: 34342859
J Endocrinol Invest. 2020 Oct;43(10):1527-1528
pubmed: 32686042
Int J Mol Sci. 2020 Sep 09;21(18):
pubmed: 32916818
J Autoimmun. 2021 Sep;123:102710
pubmed: 34332438
Autoimmun Rev. 2015 Feb;14(2):174-80
pubmed: 25461470
J Hepatol. 2021 Jul;75(1):222-224
pubmed: 33862041
Front Endocrinol (Lausanne). 2017 Jan 24;7:150
pubmed: 28167927
J Autoimmun. 2011 Feb;36(1):4-8
pubmed: 20708902
Immunol Res. 2020 Oct;68(5):310-313
pubmed: 32946016
Br J Anaesth. 2021 Mar;126(3):e106-e108
pubmed: 33386124
Thyroid. 2021 Sep;31(9):1436-1439
pubmed: 33858208
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
J Clin Endocrinol Metab. 2008 Mar;93(3):674-6
pubmed: 18326006
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101412
pubmed: 32265102
J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105906
pubmed: 34111775